CSIMarket
 
Point Biopharma Global Inc   (PNT)
Other Ticker:  
 
 
Price: $12.5000 $0.02 0.160%
Day's High: $12.51 Week Perf: 0.4 %
Day's Low: $ 12.49 30 Day Perf: -9.16 %
Volume (M): 3,291 52 Wk High: $ 14.35
Volume (M$): $ 41,136 52 Wk Avg: $9.85
Open: $12.50 52 Wk Low: $6.57



 Market Capitalization (Millions $) 1,322
 Shares Outstanding (Millions) 106
 Employees 50
 Revenues (TTM) (Millions $) 244
 Net Income (TTM) (Millions $) 97
 Cash Flow (TTM) (Millions $) -104
 Capital Exp. (TTM) (Millions $) 19

Point Biopharma Global Inc
Point Biopharma Global Inc is a rapidly growing company in the biopharmaceutical industry. The company is focused on the development, manufacturing, and commercialization of radiopharmaceuticals for the treatment of cancer. They are driven by a mission to discover, develop and deliver innovative therapies for the benefit of cancer patients around the world.

Point Biopharma Global Inc has a strong leadership team with extensive experience in the pharmaceutical industry. In addition, the company has a strategic collaboration with Endo International plc to develop and commercialize injectable radiopharmaceutical products. This collaboration enables Point Biopharma to leverage Endo's established infrastructure, scale, and expertise in the pharmaceutical industry.

The company has a portfolio of radiopharmaceuticals in various stages of development, including its lead candidate, PNT2002, for the treatment of neuroendocrine tumors. PNT2002 is a targeted therapy that selectively delivers radiation to cancer cells while sparing normal tissue. The company is also developing PNT2006 for the treatment of follicular lymphoma and other hematologic malignancies.

To ensure that their radiopharmaceutical products meet the highest quality standards, Point Biopharma has established a state-of-the-art manufacturing facility in Indianapolis, Indiana. The facility is equipped with advanced technology and equipment to manufacture radiopharmaceutical products in compliance with FDA regulations.

Point Biopharma Global Inc is committed to bringing innovative cancer treatments to patients in need. Their dedication to improving the lives of cancer patients has earned them recognition in the industry and among the medical community as a company that is poised to make a significant impact in the fight against cancer.


   Company Address: 4850 West 78th Street Indianapolis, 46268 IN
   Company Phone Number: 543-9957   Stock Exchange / Ticker: NASDAQ PNT
   PNT is expected to report next financial results on March 26, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Clinical Study

A Paradigm Shift in Prostate Cancer Treatment: Positive SPLASH Trial Results and POINT Biopharma's Resilient Growth

Published Mon, Dec 18 2023 12:30 PM UTC



In the field of oncology, breakthroughs in the treatment of metastatic castration-resistant prostate cancer (mCRPC) have remained a significant challenge. However, recent reports from Lantheus and POINT Biopharma reveal a beacon of hope for patients with this aggressive form of prostate cancer. The positive topline results of the phase 3 SPLASH trial utilizing 177L...

Point Biopharma Global Inc

Point Biopharma Global Inc's Q3 Report Reveals Impressive $2.789993M Revenue Growth, Implications for Future Growth Explored



Point Biopharma Global Inc, a renowned biopharmaceutical company, has recently released its financial results for the most recent fiscal period. While the company has witnessed a significant increase in revenue, it also faced a higher net shortfall compared to the previous year. This article aims to interpret and analyze these financial results and their potential implications for the future of Point Biopharma Global Inc.
Revenue Growth:
During the most recent fiscal period, Point Biopharma Global Inc achieved a remarkable revenue of $2.789993 million. This substantial increase in revenue suggests the company's ability to attract new customers and generate substantial sales. Such growth in revenue is certainly a positive sign for the company and indicates its potential to continue expanding its market presence.

Point Biopharma Global Inc

Point Biopharma Global Inc Generates Impressive $4.865856 Million Revenue, Amidst Net Loss, Pointing Towards Promising Future Growth Potential



Point Biopharma Global Inc, a biopharmaceutical company trading on the NASDAQ, has experienced a significant increase in stock value over the past three months and in the year 2023. Despite facing a net loss in the most recent fiscal period, the company has managed to generate substantial revenue. These factors raise questions regarding the future prospects and growth potential of Point Biopharma Global Inc.
Positive Stock Performance:
Point Biopharma Global Inc's stock has soared by 19.13% in the past three months, indicating investor confidence and interest in the company. This uptrend is further supported by a remarkable increase of 25.07% in the year 2023. Such impressive gains suggest that the market recognizes Point Biopharma Global Inc's value, creating an optimistic outlook for the company.

Point Biopharma Global Inc

Point Biopharma Global Inc Reports Strong Revenue Growth in Q1 2023 Despite Increased Net Deficit

Point Biopharma Global Inc, a leading biopharmaceutical company, has announced a revenue of $9.457264 million in the first quarter of 2023. With its focus on developing innovative treatments for challenging diseases, PNT has been an instrumental player in the biopharma industry.
However, despite the increase in revenue, PNT also revealed a larger net deficit of $-16.531 million for the first quarter of 2023, which is bigger than $-16.381 million reported a year ago. While the larger deficit may cause alarm, it is important to note that research and development of drugs is a costly process.






 

Point Biopharma Global Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com